ArticleObesity science & practice2020
Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity.
Article in Obesity science & practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Effect of dietary counseling and dietary fiber on tolerability during weight management with EMP16 and conventional orlistat: a single-blind randomized pilot trial.Scientific reports · 2026Trial
- The Supportive Effect of Acarbose to Orlistat in Weight Management-A Randomized, Double-Blind, Multiarm Phase 2 Trial.Obesity (Silver Spring, Md.) · 2025Trial
- Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: A randomized, placebo-controlled trial.Obesity (Silver Spring, Md.) · 2022Trial
- Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose.Clinical pharmacology in drug development · 2021Trial
- Physicochemical Analysis and Digestive Enzymes Inhibition of a Selected MalaysianFoods (Basel, Switzerland) · 2025Article
- Calorie restriction mimetics against aging and inflammation.Biogerontology · 2025Review
- Clinical features of pneumatosis intestinalis induced by alpha- glucosidase inhibitor in patients with type 2 diabetes mellitus: a single center retrospective study.Frontiers in endocrinology · 2025Article
- Treatment of type 2 diabetes mellitus with stem cells and antidiabetic drugs: a dualistic and future-focused approach.Human cell · 2024Review
- Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- New Therapeutic Strategies for Obesity and Its Metabolic Sequelae: Brazilian Cerrado as a Unique Biome.International journal of molecular sciences · 2023Review
- Reversal and Remission of T2DM - An Update for Practitioners.Vascular health and risk management · 2022Review
- Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity.Obesity science & practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere is an unmet medical need for a safe and effective weight loss product with minimal systemic side-effects. In this study, the effect of a novel modified-release fixed-dose combination of orlistat and acarbose (MR-OA) was compared with conventional orlistat (CO) regarding tolerability, appetite and glucose metabolism.
methodsSixty-seven men with obesity, aged 24 to 60 years with body mass indexes (BMIs) 33 to 40 kg m
resultsIn the MR-OA groups, reports of liquid and oily stools as well as faecal incontinence were fewer, whereas reports of gastric distension and flatulence were higher, compared with the CO group. More participants reported decreased hunger in the 90/30 and 120/40 MR-OA, and postprandial plasma glucose concentration was reduced in all MR-OA groups compared with CO.
conclusionsThis study shows that by using a modified-release dosage form, orlistat and acarbose can be combined without compromising tolerability. Furthermore, MR-OA shows promising effects regarding reduction of appetite and reduces postprandial glucose. Tolerability is coupled to compliance and thereby efficacy of a treatment; therefore, this novel combination MR-OA could be an effective approach for weight loss treatment. A follow-up study in a more diverse population and for a longer duration with weight loss as primary outcome variable is planned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.